Compare Boston Beer Company Inc (SAM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs TG Therapeutics Inc — how do they compare? Boston Beer Company Inc trades at $179.73 (market cap $1.86B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 4.1× Boston Beer Company Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| SAM | TGTX | |
|---|---|---|
Market Cap | $1.86B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $59.06 |
52-Week Low | $161.08 | $26.94 |
Enterprise Value | $1.63B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer (SAM) trades at $183.78, up 1.54% on the day, amid a bearish technical signal and mixed fundamentals. Recent quarterly earnings have missed expectations, with Q2 2026 EPS of $3.65 falling short of the $4.83 estimate, though Q4 2025 beat. The company shows improved net income margins in 2025 but faces revenue pressure and negative ROE/ROA. Analyst consensus is a $207.33 price target with a majority Hold rating, while cash flow trends show recent stabilization after a net outflow in 2024.
The outlook is cautious due to weak volume trends and competitive pressures, offset by a debt-free balance sheet and margin gains. Risks include declining core brands and macroeconomic headwinds, but innovation in RTD beverages offers growth potential. Investors should weigh valuation support against earnings volatility and sentiment headwinds.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
